- Home
- WRB vs MRNA Comparison
WRB vs MRNA Comparison
Compare WRB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | MRNA |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | 8804 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 21.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WRB | MRNA |
|---|---|---|
| Price | $70.25 | $61.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 12 |
| Target Price | ★ $68.86 | $34.27 |
| AVG Volume (30 Days) | 2.0M | ★ 6.8M |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $5.18 | $9.36 |
| Revenue Next Year | $4.95 | $15.43 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $62.87 | $22.28 |
| 52 Week High | $78.96 | $67.74 |
Technical Indicators
Market Signals| Indicator | WRB | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 65.83 |
| Support Level | $65.14 | $45.69 |
| Resistance Level | $71.18 | N/A |
| Average True Range (ATR) | 1.36 | 4.36 |
| MACD | 0.25 | 1.49 |
| Stochastic Oscillator | 96.21 | 73.05 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.